6月29日，康方生物盘中上涨3.66%，报85.6港元，成交额1.58亿港元，股价自52周低点附近反弹。消息面上，全球知名生物医药分析机构Evaluate最新发布《全球最具价值研发项目》榜单，公司核心产品依沃西以超252亿美元风险调整后净现值位列全球在研管线价值第一，系前十中唯一中国自主研发原创新药，机构预计其2032年全球销售额将达85亿美元。此前股价因ASCO利好兑现后获利了结累计跌逾30%逼近52周低点80.2港元，该榜单消息有望修复市场对公司核心资产的价值认知。同板块荣昌生物涨4.24%、信达生物涨1.0%，生物科技板块整体回暖。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.